SCOR holds its course: combining growth, profitability and solvency to record a net result of EUR 330 million in 2011.

SCOR informe que son Document de référence 2011 a été déposé auprès de l’Autorité des marchés financiers (AMF) le 8 mars 2012.

SCOR tient son cap en conjuguant croissance, rentabilité et solvabilité, avec un résultat net de EUR 330 millions en 2011

Document PDF

The subject of this note is to propose a set of analytical methods to derive a “closed-form solution” for MVM for a Non-Life insurance company, from a theoretical model first, and then to fit this model to a given set

Le don de rein se développe partout dans le monde, certains pays à la pointe dans ce domaine, comme les Etats-Unis et le Japon, pays d’origine des études que nous avons exploitées pour cette publication.

SCOR Global P&C has recorded a very satisfactory increase in its business in 2011: gross written premiums are up by 8.8% to EUR 3.982 billion at current exchange rates.

SCOR réussit les renouvellements du 1er janvier 2012 : croissance de 13,9 %, conditions tarifaires satisfaisantes (+2 %) et rentabilité technique attendue

SCOR Global P&C has recorded a very satisfactory increase in its business in 2011: gross written premiums are up by 8.8% to EUR 3.982 billion at current exchange rates.

SCOR successfully concludes the January 1, 2012 renewals: 13.9% growth, satisfactory pricing conditions (+2%) and expected technical profitability.

The Continuous Mortality Investigation (CMI) has recently published Working Papers 52 and 58. These Papers represent a third phase in the activity of the CMI Critical Illness Committee.